ArticleBMC infectious diseases2026
Risk factors affecting severe pneumococcal pneumonia in children: a retrospective study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Complete Blood Count-Derived Inflammatory Markers in Pediatric Lower Respiratory Tract Infection: A Narrative Review.Pathogens (Basel, Switzerland) · 2026Review
- Clinical characteristics, co-detection patterns and prognostic risk factors of human metapneumovirus infection in children: a retrospective study.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo identify risk factors for severe Streptococcus pneumoniae pneumonia (SPP) in children, and to analyze the characteristics of co-infection, drug resistance, and vaccine serotype distribution.
methodsA retrospective cohort study was conducted. The clinical data, laboratory parameters, etiological co-infections, antibiotic resistance, and vaccine serotype coverage rates were collected and compared between the severe SPP and non-severe SPP groups.
resultsA total of 203 children were included in the study. Univariate analysis revealed that the median age, fever duration, CRP, PCT, neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) were significantly higher in the severe SPP group than in the non-severe SPP group (P < 0.05). Multivariate analysis identified older age, elevated NLR, and longer fever duration as independent risk factors for severe SPP. The area under the receiver operating characteristic (ROC) curve for the combined prediction of the three was 0.802, the highest. Severe SPP combined with mycoplasma pneumoniae (MP) infection rate was higher (P < 0.05), but the incidence of wheezing was instead lower in this subgroup (P < 0.05). Antibiotic resistance profiles did not differ significantly between groups, with the highest resistance rate to erythromycin (over 90%) and the lowest to penicillin (1.4%–1.8%). The vaccination rate with the 13-valent pneumococcal conjugate vaccine (PCV13) was low in both groups (9.1% severe vs. 4.7% non-severe). There were no significant differences in PCV13 serotype coverage (58.2% severe vs. 55.4% non-severe).
conclusionHigher median age, elevated NLR, and longer duration of fever are independent risk factors for severe SPP in children, and their combination effectively predicts disease severity. Co-infection with MP may increase the risk of severe disease but alter the clinical phenotype. Clinical treatment should focus on the high macrolide resistance, and penicillins may be preferred. Currently, the vaccination rate for PCV13 is low, and increasing this rate is the primary task to prevent this disease. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.